Business Wire

ESI-GROUP/JMDA-DESIGN

22.10.2020 09:02:04 CEST | Business Wire | Press release

Share
ESI Virtual Prototyping Supports JMDA’s Red Dot Award

With a relationship that spans more than a decade, JMDA Design and ESI Group (Paris:ESI) worked together on the Tinyseats child car seat project which resulted in the highly acclaimed Red Dot Award: Design Concept 2020.

Multi-award winning JMDA Design has collaborated with ESI Group, a global player in virtual prototyping software and services for industrials, for many years. Their unique partnership enabled the Tinyseats child car seat project from Tinyseats Europe AB to undergo rigorous testing without the need of any physical prototypes. They were able to do this at the early stages of development to gain additional information about product performance and to help de-risk compliance challenges in a test situation. Using Virtual Prototyping by working with ESI Group, particularly for innovative, cutting-edge child restraint systems (CRS), ensures dynamic performance is optimised with controlled time and investment, from the upstream phases of the product design process.

Derrick Barker, Founder and Director at JMDA explains, “The Red Dot Award: Design Concept 2020 for the Tinyseats child car seat was a ground-breaking project aiming to achieve a very lightweight, compact and convertible car seat for children from 9 months old. Working with ESI Group enabled JMDA to gain substantial insight into the performance of the car seat early on in the design process, especially the load bearing structure, which could be fully evaluated in a virtual environment.” Derrick adds, “As our relationship goes from strength to strength with ESI Group we are backed by a team sharing our passion for innovation with the highest safety standards”.

We are really proud to be part of JMDA journey for many years now. Their commitment toward safety and comfort compelled with their undisputed design expertise make them a key player in the car seat industry. Helping industrials to commit to such outcome is truly embarked in our DNA and our strategy. This Red Do Award proves that allowing any compromise between, design, safety and performance is possible with the appropriate expertise, solutions and trust-based relationship .” declares Jonas Fredriksson, Managing Director – ESI Northern Europe

JMDA Design, a global provider for product design services with nearly 30 years’ experience in the industry, is currently designing their 105th child car seat, have. Partnering with world leading specialists, like ESI Group, is a critical part of ensuring a truly holistic approach to innovative product design.

About ESI

Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation.

Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high level specialists. In 2019, its proforma turnover was 146.2M€. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information, go to www.esi-group.com .

For more information about the partnership between JMDA Design and ESI Group, please give Derrick Barker a call on +44 (0) 1386 426100 or email derrick.barker@jmda.co.uk .

- ENDS -

Notes to Editor

- JMDA Design specialise in the design and development of a diverse range of products including child car seats, stair lifts, showers, smoke alarms and highchairs.
- JMDA Design have two offices one in Pershore, Worcestershire and one in Shanghai, China.
- They support clients across the world with testing, manufacturing and distribution of the products they design.
- Awards for innovation and international activity include:

2020 – Winners of Red Dot Award: Design Concept 2020
2019 - Winners of The Queen’s Awards for Enterprise: International Trade 2019
2019 – Winners of a German Design Award 2020
2018 – International Design Award Winners
2017 - Highly Commended ‘Exporter of the Year’ - Hereford and Worcestershire Chamber of Commerce Awards
2016 – Winners of Red Dot Award: Design Concept 2016
2014 – Winner of the Progressive Preschool Innovation Award (Flippa Folding Dining Booster)
2012 – Finalist of the Hereford and Worcestershire Chamber of Commerce International Business Award
2010 – Winner of the International Business of the Year Award
2009 – Finalist of the Kind & Jugend Innovation Award
2008 – Finalist of the Kind & Jugend Innovation Award
2008 – Finalist of the Chamber of Commerce Small Business of the Year Award

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye